Vaccine clinical trials with RNA-Sequence endpoints to measure gene expression
- Lessons Learned
RNA-Sequencing (RNA-Seq) is a revolutionary technology that enables researchers to assess gene expression changes in thousands of genes over time. Results provide deep insights into mechanistic processes such which innate and adaptive immune system processes are activated following vaccination and when. However, the analysis of this data is not trivial requiring special statistical and computational skills due to its sheer size and complexity. In addition, RNA-Seq experiments are costly and careful experimental design considerations can save a lot of money.
In this webinar, we will provide an overview of our experience with supporting vaccine clinical trials with RNA-Seq endpoints to measure gene expression based on RNA extracted from blood, PBMC, or immune cell subsets at multiple timepoints.
The presentation will discuss several vaccine trials, experimental designs, analysis strategies, select results, and lessons learned including criteria for timepoint and immune cell type selection, optimization of experimental and analytical parameters, and ways to avoid common pitfalls. Anyone working on or interested in using RNA-Seq as part of pre-clinical vaccine development or as part of clinical trials will benefit from this discussion.
Key Learning Objectives
- Best practices for RNA-Seq as part of pre-clinical vaccine development
- Design considerations to save cost in RNA-Seq experiments
- Expert tips in supporting vaccine clinical trials with RNA-Seq endpoints
- How to avoid common pitfalls in several types of vaccine trials
Find out how Emmes is making advances by downloading the webinar today!